Multiple sclerosis

• PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial. Not authorised
  2025-520955-10-00 4
• Effects of GLP-1 analogue in multiple sclerosis Pending
  2024-519235-42-00 4 "Patients with confirmed multiple sclerosis (MS), with worse "
• HiHat trial Pending
  2024-519700-28-01 4 "Patients with relapsing-remitting multiple sclerosis with le"
• Hydroxychloroquine in progressive MS Pending
  2025-522573-11-00 4 "Multiple Sclerosis"
• A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammatio … Pending
  2026-525817-29-00 4 "Multiple Sclerosis; Primary Progressive Multiple Sclerosis; "
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting
  2023-504358-36-00 5 2024-10-17 "multiple sclerosis"
• Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting
  2024-511686-11-00 5 2021-10-05 "Multiple Sclerosis in pediatric patients"
• Non-inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple s … Recruiting
  2024-519304-28-00 5 2026-04-20 "Multiple Sclerosis"
• MB-CART2019.1 in refractory MS Recruiting
  2024-517601-82-00 9 2026-04-01 "refractory Multiple Sclerosis"
• A Phase 1, drug-drug interaction trial of IMU-838 with oral contraceptives in women Recruiting
  2026-525208-90-00 3 2026-04-01
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 "Progressive Forms of Multiple Sclerosis (PMS)"
• Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasti … Recruiting
  2024-517745-14-00 4 2025-09-24 "Multiple Sclerosis Spasticity"
• The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary pr … Recruiting
  2024-514549-12-00 6 2025-06-16 "Multiple Sclerosis"
• MODAFIMS: An open-label, single-center clinical trial to evaluate predictors of response to MODAFinil in the treatment of cognitive deficits … Recruiting
  2022-501414-53-00 4 2024-08-21
• SMART-MS Recruiting
  2023-510228-63-00 4 2024-05-01
• A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous a … Recruiting
  2023-509357-31-00 1 2021-06-01 "Multiple Sclerosis (MS)"
• A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruitment ended
  2024-517980-22-00 4 2025-12-10 "Multiple Sclerosis (MS)"
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Recruitment ended
  2023-504359-29-01 5 2024-12-11
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruitment ended
  2024-514343-29-00 5 2024-11-19 "multiple sclerosis"
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Recruitment ended
  2022-501622-37-00 5 2024-01-16 "Multiple Sclerosis"
• Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb … Recruitment ended
  2023-503190-38-00 4 2023-11-23 "Progressive Multiple Sclerosis"
• Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Recruitment ended
  2022-502664-21-00 6 2023-05-01 "multiple sclerosis"
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Recruitment ended
  2023-505974-14-00 5 2022-06-23 "Multiple Sclerosis (MS)"
• Proof-of-concept study for SAR441344 (frexalimab) in relapsing multiple sclerosis. Recruitment ended
  2024-513527-17-00 4 2021-06-07 "Multiple Sclerosis"

Showing 1–24 of 42 trials